Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics
Arcus Biosciences, Inc. (RCUS)
Today's Latest Price: $37.00 USD
Updated Jan 27 7:45am
Add RCUS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RCUS Stock Summary
- The ratio of debt to operating expenses for Arcus Biosciences Inc is higher than it is for about merely 0.52% of US stocks.
- RCUS's price/sales ratio is 30.07; that's higher than the P/S ratio of 92.01% of US stocks.
- Revenue growth over the past 12 months for Arcus Biosciences Inc comes in at 1,041.81%, a number that bests 99.21% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Arcus Biosciences Inc, a group of peers worth examining would be MORF, XENE, VYGR, NTLA, and FULC.
- Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.
RCUS Stock Price Chart Interactive Chart >
RCUS Price/Volume Stats
| Current price | $37.00 | 52-week high | $40.01 |
| Prev. close | $36.03 | 52-week low | $8.55 |
| Day low | $37.00 | Volume | 409 |
| Day high | $37.00 | Avg. volume | 531,789 |
| 50-day MA | $30.05 | Dividend yield | N/A |
| 200-day MA | $25.70 | Market Cap | 2.40B |
Arcus Biosciences, Inc. (RCUS) Company Bio
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.
Loading social stream, please wait...